

THE UNIVERSITY OF MICHIGAN
REGENTS COMMUNICATION

ACTION REQUEST

Subject: Project Agreements with the University of Michigan

Action Requested: Authorization to enter into or amend Agreements

Preamble:

Statutory conflicts of interest situations were identified by the Office of Research and Sponsored Projects while reviewing Proposal Approval Forms that then triggered a review by the Medical School Conflict of Interest Board and/or the OVPR Conflict of Interest Committee. Plans for management of the possible risks associated with the conflicts of interest will be developed and approved by the Board and/or Committee and may require agreement by the parties involved at time of award.

These proposed project (e.g., research, sponsored activity, and/or subcontract) agreements (“Agreement”) and/or amendments to Agreements (“Amendments”) fall under the State of Michigan Conflict of Interest Statute because University of Michigan (“University”) employees have activities, relationships, or interests in the companies as described in Attachment A. The law permits such Agreements provided they are disclosed to the Board of Regents (“Regents”) of the University and approved in advance by a 2/3 vote.

Agreement Terms:

The terms of the Agreements and/or Amendments conform to University policy. The funding support will not exceed the amount reported in Attachment A for each Agreement and/or Amendment. Since projects are often amended, these Agreements and/or Amendments include provisions for changes in time and scope. University procedures for approval of these changes will be followed and additional conflict of interest review will be done as appropriate.

Impact of the Agreement:

The Agreements and/or Amendments will provide support of investigator’s effort to use their expertise and University laboratories, as well as other University resources, to execute the projects as reported in Attachment A.

Recommendations:

These matters have been reviewed and approved by the Medical School Conflict of Interest Board and/or the OVPR Conflict of Interest Committee. In light of this disclosure and our finding that the Agreements and Amendments were negotiated in conformance with standard University practices, I recommend that the Board of Regents approve the University’s entering into or amending the Agreements referenced in Attachment A.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Arthur Lupia". The signature is fluid and cursive, with the first name "Arthur" and last name "Lupia" clearly distinguishable.

Arthur Lupia
Interim Vice President for Research and Innovation

March 2025

Attachment A

Project #1

SBIR Phase I Subcontract Agreement between the University and Arborsense, Inc. Reviewed by the Medical School Conflict of Interest Board and the OVPR Conflict of Interest Committee	
<u>Project Information</u>	
Title: A wearable alcohol monitor to detect low-level drinking	U-M Project ID: 25-PAF01521
Direct Sponsor: Arborsense, Inc.	Prime Sponsor: National Institutes of Health
Principal Investigator/Department: Xudong Fan, Biomedical Engineering	
Project Duration: Six (6) Months	Funding Support: \$61,159
Purpose: The purpose of this project is to develop a wearable alcohol monitor to detect low-level drinking.	
<u>University Employee; University Title; Relationship with Arborsense, Inc.</u> <ul style="list-style-type: none">● Xudong Fan; Professor, Biomedical Engineering; Partial Owner● Zhaohui Zhong; Associate Professor, Electrical Engineering and Computer Science – Electrical and Computer Engineering (EECS – ECE) Division; Partial Owner● Mark Ilgen; Professor, Psychiatry; Partial Owner	

Project #2

SBIR Phase I Subcontract Agreement between the University and ASKO Therapeutics, Inc. Reviewed by the OVPR Conflict of Interest Committee	
<u>Project Information</u>	
Title: Novel Injectable Implants for Long-term Local Controlled Release of Therapeutic Monoclonal Antibodies	U-M Project ID: 25-PAF00965
Direct Sponsor: ASKO Therapeutics, Inc.	Prime: National Institutes of Health
Principal Investigator/Department: Steven Schwendeman, Pharmaceutical Sciences	
Project Duration: One (1) Year	Funding Support: \$115,000
Purpose: The purpose of this project is to develop novel, simple, efficient, and generalizable Poly(lactic-co-glycolic) acid (PLGA) implants for slow and continuous release of therapeutic monoclonal antibodies.	
<u>University Employee; University Title; Relationship with ASKO Therapeutics, Inc.</u>	
<ul style="list-style-type: none">● Anna Schwendeman; Professor, Pharmaceutical Sciences; Partial Owner● Steven Schwendeman; Professor, Pharmaceutical Sciences; Partial Owner● Vishalakshi Krishnan; Associate Director, Center for Research on Complex Generics; Partial Owner	

Project #3

STTR Phase I Subcontract Agreement between the University and RegenEir LLC Reviewed by the OVPR Conflict of Interest Committee	
<u>Project Information</u>	
Title: Local Delivery Formulations for Oral Cancer Immunochemoprevention	U-M Project ID: 25-PAF01637
Direct Sponsor: RegenEir LLC	Prime: National Institutes of Health
Principal Investigator/Department: Joerg Lahann, Chemical Engineering	
Project Duration: Three (3) Years	Funding Support: \$230,500
Purpose: The purpose of this project is to characterize and optimize the Janus-nanoparticles (JNP) formulation for co-delivery of tocilizumab (TCZ) and avelumab (AVE).	
<u>University Employee; University Title; Relationship with RegenEir LLC</u>	
<ul style="list-style-type: none">● Joerg Lahann; Professor, Chemical Engineering; Partial Owner	

Project #4

SBIR Phase II Subcontract Agreement between the University and Rydberg Technologies Inc. Reviewed by the OVPR Conflict of Interest Committee	
<u>Project Information</u>	
Title: Quantum Cal Laboratory (QCAL) Phase II	U-M Project ID: 25-PAF05647
Direct Sponsor: Rydberg Technologies Inc.	Prime Sponsor: Department of Defense- Defense Advanced Research Projects Agency
Principal Investigator/Department: Alexander Burgers, EECS – ECE Division	
Project Duration: Three (3) Years	Funding Support: \$1,200,000
Purpose: The purpose of this project is to support the implementation of a Rydberg Technologies Inc. vapor cell/Electromagnetically Induced Transparency (EIT) setup, including test procedures and establishing an EM RF-shielded facility, by developing a prototype EIT system for initial testing and transfer the design and prototype to the QCAL facility for integration with RF testing systems and signal processing electronics.	
<u>University Employee; University Title; Relationship with Rydberg Technologies Inc.</u>	
<ul style="list-style-type: none">• Georg Raithel; Professor, Physics; Partial Owner	

Project #5

SBIR Phase IIB Subcontract Agreement between the University and Theia Scientific, LLC Reviewed by the OVPR Conflict of Interest Committee	
<u>Project Information</u>	
Title: An Open Analysis Platform with In-SituMachine Vision for Electron Microscopy	U-M Project ID: 25-PAF03486
Direct Sponsor: Theia Scientific, LLC	Prime Sponsor: Department of Energy
Principal Investigator/Department: Kevin Field, Nuclear Engineering & Radiological Sciences	
Project Duration: Two (2) Years	Funding Support: \$330,000
Purpose: The purpose of this project is to extend commercialization efforts of Theia Scientific, LLCs technology to include tasks beyond the original scope of the initial SBIR Phase II award related to the expansion of the number of machine learning models hosted on learning platforms.	
<u>University Employee; University Title; Relationship with Theia Scientific, LLC</u>	
<ul style="list-style-type: none">• Kevin Field; Associate Professor, Nuclear Engineering & Radiological Sciences; Partial Owner	